Beneficial effects of JAK inhibitor therapy in Systemic Mastocytosis

Br J Haematol. 2017 Jan;176(2):324-327. doi: 10.1111/bjh.13951. Epub 2016 Feb 5.

Authors

Robin Dowse¹, Maria Ibrahim¹, Donal P McLornan^{1

2}, Mufaddal T Moonim³, Claire N Harrison², Deepti H Radia²

Affiliations

¹ Department of Haematological Medicine, King's College NHS Foundation Trust, London, UK.
² Department of Haematology, Guy's and St. Thomas' NHS Foundation Trust, London, UK.
³ Department of Pathology, Guy's and St. Thomas' NHS Foundation Trust, London, UK.

PMID: 26847591
DOI: 10.1111/bjh.13951

No abstract available

Keywords: JAK; mastocytosis; spleen.

Publication types

Case Reports

MeSH terms

Female
Humans
Janus Kinase Inhibitors / administration & dosage
Janus Kinase Inhibitors / pharmacology
Janus Kinase Inhibitors / therapeutic use*
Mastocytosis, Systemic / drug therapy*
Mastocytosis, Systemic / pathology
Middle Aged

Substances

Janus Kinase Inhibitors